Source: GlobalNewswire

Press Release: Lee's Pharm : Lee's Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Breakthrough Therapy Designation in China for the Treatment of Recurrent or Metastatic Cervical Cancer

HONG KONG and SAN DIEGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- China Oncology Focus Limited (COF), an affiliate of Lee's Pharmaceutical Holdings Limited (Lee's Pharma, HKEX: 950), and Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE), today announced that its anti-PD-L1 antibody, socazolimab, licensed from Sorrento to COF for the greater China territory, has been granted breakthrough therapy designation (BTD) by the China National Medical Products Administration (NMPA) to treat recurrent or metastatic cervical cancer.

Read full article »
Est. Annual Revenue
Est. Employees
CEO Avatar


Update CEO

CEO Approval Rating

- -/100

Lee's Pharm is a Private company. Lee's Pharm generates $1M in revenue per employee Lee's Pharm has 2 followers on Owler.